Pluvicto had sales of just under $1Bil last year, just missing official blockbuster drug status, Novartis predicts peak sales of $2Bil per annum.
The expectation is(from the above analysis), our product will compete head to head with it. Just one of many potential revenue opportunities for Clarity.
Our small molecule binding agent works better than anything else judging by the imaging results so far.
Sounds v good to me.
-
- There are more pages in this discussion • 1,114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.19 |
Change
0.280(7.16%) |
Mkt cap ! $1.355B | |||
| Open | High | Low | Value | Volume |
| $3.93 | $4.23 | $3.92 | $19.06M | 4.603M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1651 | $4.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.22 | 11878 | 4 |
View Market Depth
| Last trade - 16.14pm 22/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |